NEW SALE OF THE ROSA ROBOTIC SURGERY SYSTEM IN FRANCE
Montpellier, France, February 15, 2016 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, has announced another sale of its ROSA™ robotic surgery system to Rouen University Hospital in Normandy, France.
Rouen University Hospital is a prestigious center in the field of neurosurgery, particularly for the treatment of epilepsy. Le Point magazine (a weekly review similar to Time Magazine or Newsweek) ranked the hospital among the top 10 French hospitals caring for patients suffering from epilepsy.
“The neurosurgery department will now be able to use the ROSA™ system's innovative robotic technology to perform minimally invasive procedures for the benefit of our patients. The addition of the ROSA™ robot enhances our position as a center of excellence in neurosurgery equipped with the latest innovations,” said Dr. Stéphane Derrey, neurosurgeon specializing in the treatment of neurological disorders at Rouen University Hospital.
Bertin Nahum, CEO and Founder of Medtech, commented, “We are pleased that another French hospital has selected the ROSA™ robot as a key component of their investment in new technologies. France has the second largest installed base of ROSA™ systems after the United States, highlighting the strong pace of adoption in our home market and the evolution in the care services that French hospitals have to offer.”
|
About MEDTECH Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment. In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada. In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan. In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine. In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards. In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan. In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category. In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine. |
|
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 4 67 10 77 40 |
INVESTORS Corinne Puissant Tel : +33 1 53 67 36 77 [email protected] |
PRESS Alexandra Prisa (EU) Tel. : +33 1 53 67 36 90 [email protected] |
Joanna Zimmerman (US) Tel : +1 646-536-7006 [email protected] |
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-43123-VENTE-ROSA-CHU-ROUEN_ENG_VDEF.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Quelle: Actusnews
